H. pylori infection and gastric cancer: State of the art (Review)

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 5-18

  Conteduca, Vincenza ^a   Sansonno, Domenico ^a   Lauletta, Gianfranco ^a   Russi, Sabino ^a   Ingravallo, Giuseppe ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Endoscopic surveillance; Gastric cancer; Gastric polyps; Helicobacter pylori; Helicobacter pylori eradication; Mucosa associated lymphoid tissue lymphoma

Indexed keywords

ACETYLSALICYLIC ACID; ADHESIN; AMOXICILLIN; ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; BETA CATENIN; BISMUTH CITRATE; CAGA PROTEIN; CELL ADHESION MOLECULE; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; GASTRIN; INDIGO CARMINE; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LEVOFLOXACIN; METRONIDAZOLE; MUCIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN I; PEPSINOGEN II; PROTON PUMP; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; UVOMORULIN; VACUOLATING TOXIN;

ADENOMATOUS POLYP; ATROPHIC GASTRITIS; BACTERIAL VIRULENCE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CELL CYCLE PROGRESSION; DYSPLASIA; ESOPHAGOGASTRODUODENOSCOPY; FAMILIAL CANCER; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; INTESTINE METAPLASIA; LYMPHOCYTE PROLIFERATION; MARGINAL ZONE LYMPHOMA; PATHOGENICITY ISLAND; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SALVAGE THERAPY; STAINING; STOMACH ACID SECRETION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH POLYP; STOMACH SECRETION; STOMACH ULCER; TREATMENT DURATION; UREA BREATH TEST;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS;

EID: 84873687878     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1701     Document Type: Review

References (77)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Kim SS, Ruiz VE, Carroll JD and Moss SF: Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett 305: 228-238, 2011.
3. Suerbaum S and Michetti P: Helicobacter pylori infection. N Engl J Med 347: 1175-1186, 2002.
4. Fuccio L, Eusebi LH and Bazzoli F: Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol 2: 342-347, 2010.
5. Conteduca V, Sansonno D, Ingravallo G, et al: Barrett's esophagus and esophageal cancer: an overview. Int J Oncol 41: 414-424, 2012.
6. Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362, 2006. (Pubitemid 43329250)
7. Polk DB and Peek RM Jr: Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10: 403-414, 2010.
8. Zullo A, Hassan C, Cristofari F, et al: Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 8: 105-110, 2010.
9. Fuccio L, Zagari RM, Eusebi LH, et al: Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151: 121-128, 2009.
10. Yaghoobi M, Bijarchi R and Narod SA: Family history and the risk of gastric cancer. Br J Cancer 102: 237-242, 2010.
11. IARC Working Group: Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7 14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61: 1-241, 1994.
12. De Vries AC, Haringsma J and Kuipers EJ: The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 12: 1-15, 2007. (Pubitemid 46105914)
13. Correa P: A human model of gastric carcinogenesis. Cancer Res 48: 3554-3560, 1998.
14. Watanabe T, Tada M, Nagai H, Sasaki S and Nakao M: Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 115: 642-648, 1998. (Pubitemid 28397299)
15. Correa P and Houghton J: Carcinogenesis of Helicobacter pylori. Gastroenterology 133: 659-672, 2007. (Pubitemid 47187360)
16. Hatakeyama M: Helicobacter pylori CagA-a bacterial intruder conspiring gastric carcinogenesis. Int J Cancer 119: 1217-1223, 2006. (Pubitemid 44258793)
17. Konturek PC, Konturek SJ and Brzozowski T: Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 60: 3-21, 2009.
18. Gianfagna F, De Feo E, van Duijn CM, Ricciardi G and Boccia S: A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 9: 361-374, 2008.
19. González CA, Figueiredo C, Lic CB, et al: Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol 106: 867-874, 2011.
20. Liu D, He Q and Liu C: Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia. J Gastroenterol Hepatol 25: 795-799, 2010.
21. Hold GL, Rabkin CS, Chow WH, et al: A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132: 905-912, 2007. (Pubitemid 46440859)
22. Nobili S, Bruno L, Landini I, et al: Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 17: 290-299, 2011.
23. Lu XX, Yu JL, Ying LS, et al: Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 118: 5507-5517, 2012.
24. Rocco A, Compare D and Nardone G: Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. World J Gastrointest Oncol 4: 54-59, 2012.
25. Suarez F, Lortholary O, Hermine O, et al: Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107: 3034-3044, 2006.
26. Carmack SW, Genta RM, Graham DY and Lauwers GY: Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 6: 331-341, 2009.
27. Kelly PJ and Lauwers GY: Clinical guidelines: Consensus for the management of patients with gastric polyps. Nat Rev Gastroenterol Hepatol 8: 7-8, 2011.
28. Malfertheiner P, Megraud F, O'Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781, 2007. (Pubitemid 46854190)
29. Malfertheiner P, Megraud F, O'Morain CA, et al: Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 61: 646-664, 2012.
30. De Vries AC and Kuipers EJ: Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 12: 22-31, 2007. (Pubitemid 350076223)
31. Schlemper RJ, Itabashi M, Kato Y, et al: Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 349: 1725-1729, 1997. (Pubitemid 27252671)
32. Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47: 251-255, 2000. (Pubitemid 30489769)
33. Dixon MF: Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 51: 130-131, 2002. (Pubitemid 34717758)
34. Rugge M, Pennelli G, Pilozzi E, et al: Gastritis: the histology report. Dig Liver Dis 43 (Suppl 4): S373-S384, 2011.
35. Ohnita K, Isomoto H, Shikuwa S, et al: Magnifying chromoendoscopic findings of early gastric cancer and gastric adenoma. Dig Dis Sci 56: 2715-2722, 2011.
36. Yeh JM, Hur C, Kuntz KM, Ezzati M and Goldie SJ: Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 116: 2941-2953, 2010.
37. Hamashima C, Shibuya D, Yamazaki H, et al: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 38: 259-267, 2008. (Pubitemid 351583989)
38. Fock KM, Katelaris P, Sugano K, et al: Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24: 1587-1600, 2009.
39. Zullo A, Hassan C, Cristofari F, Perri F and Morini S: Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2: 181-186, 2010.
40. Oh SY, Kim WS, Kim JS, et al: Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Int J Hematol 92: 510-517, 2010.
41. Shinagare AB, Ramaiya NH, O'Regan K, Jagannathan JP, Hornick JL and LaCasce AS: Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 29: 297-300, 2011.
42. Zucca E and Dreyling M; ESMO Guidelines Working Group: Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v175-v176, 2010.
43. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al: EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60: 747-758, 2011.
44. Goddard AF, Badreldin R, Pritchard DM, et al; British Society of Gastroenterology: The management of gastric polyps. Gut 59: 1270-1276, 2010.
45. Fitzgeral RC, Hardwick R, Huntsman D, et al: Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47: 436-444, 2010.
46. Guilford P, Humar B and Blair V: Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric cancer 13: 1-10, 2010.
47. Bornschein J, Rokkas T, Selgrad M and Malfertheiner P: Helicobacter pylori and clinical aspects of gastric cancer. Helicobacter 14 (Suppl 1): 41-45, 2009.
48. Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008.
49. Take S, Mizuno M, Ishiki K, et al: The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 46: 318-324, 2011.
50. Kodama M, Murakami K, Okimoto T, et al: Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion 85: 126-130, 2012.
51. Correa P, Fontham ET, Bravo JC, et al: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92: 1881-1888, 2000. (Pubitemid 32036918)
52. Wong BC, Lam SK, Wong WM, et al: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187-194, 2004. (Pubitemid 38082812)
53. Leung WK, Lin SR, Ching JY, et al: Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 53: 1244-1249, 2004. (Pubitemid 39120105)
54. Mera R, Fontham ET, Bravo LE, et al: Long term follow up of patients treated for Helicobacter pylori infection. Gut 54: 1536-1540, 2005. (Pubitemid 41531767)
55. Zhou LY, Lin SR, Ding SG, et al: The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chin J Dig Dis 6: 114-115, 2005. (Pubitemid 41783306)
56. You WC, Brown LM, Zhang L, et al: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98: 974-983, 2006. (Pubitemid 44288162)
57. Kato M, Asaka M, Nakamura T, et al: Helicobacter pylori eradication prevents the development of gastric cancer - results of a long-term retrospective study in Japan. Aliment Pharmacol Ther 24: 203-206, 2006.
58. Take S, Mizuno M, Ishiki K, et al: Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 42 (Suppl 17): 21-27, 2007. (Pubitemid 46140359)
59. Takenaka R, Okada H, Kato J, et al: Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 25: 805-812, 2007. (Pubitemid 46434921)
60. Ogura K, Hirata Y, Yanai A, et al: The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 42: 279-283, 2008. (Pubitemid 351301494)
61. Mabe K, Takahashi M, Oizumi H, et al: Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 15: 4290-4297, 2009.
62. Kuo SH, Yeh KH, Wu MS, et al: Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood 119: 4838-4844, 2012.
63. Park HS, Kim YJ, Yang WI, Suh CO and Lee YC: Treatment and outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 16: 2158-2162, 2010.
64. Gill H, Chim CS, Au WY, et al: Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. Ann Hematol 90: 1399-1407, 2011.
65. Owens SR and Smith LB: Molecular aspects of H. pylori-related MALT lymphoma. Patholog Res Int 2011: 193149, 2011.
66. O'Connor A, Gisbert JP, McNamara D and O'Morain C: Treatment of Helicobacter pylori infection 2010. Helicobacter 15: 46-52, 2010.
67. Graham DY and Fischbach L: Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010.
68. Malfertheiner P, Bazzoli F, Delchier JC, et al: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377: 905-913, 2011.
69. Kang JM, Kim N, Lee DH, et al: Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol 23: 1287-1291, 2008.
70. Perri F, Manes G, Neri M, Vaira D and Nardone G: Helicobacter pylori antigen stool test and 13C-Urea breath test in patients after eradication treatments. Am J Gastroenterol 97: 2756-2762, 2002. (Pubitemid 35265425)
71. World Gastroenterology Organisation: World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol 45: 383-388, 2011.
72. Czinn SJ and Blanchard T: Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 8: 133-140, 2011.
73. Moss SF, Moise L, Lee DS, et al: HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 29: 2085-2091, 2011.
74. Othman MO and Wallace MB: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) in 2011, a Western perspective. Clin Res Hepatol Gastroenterol 35: 288-294, 2011.
75. Pandalai PK, Lauwers GY, Chung DC, Patel D and Yoon SS: Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 149: 347-355, 2011.
76. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ and Lin JT: Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 28: 2952-2957, 2010.
77. Navarro Silvera SA, Mayne ST, Risch HA, et al: Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol 21: 543-550, 2011.